Comparative Pharmacology
Head-to-head clinical analysis: ERMEZA versus ERTACZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERMEZA versus ERTACZO.
ERMEZA vs ERTACZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ERMEZA (ivacaftor) is a CFTR potentiator that increases the open probability of the cystic fibrosis transmembrane conductance regulator (CFTR) protein at the cell surface, enhancing chloride transport in epithelial cells with specific CFTR mutations.
Sertaconazole (the active ingredient in ERTACZO) inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
1.5 mg/kg intravenously over 30 minutes every 4 weeks.
Apply a thin layer to the affected area once daily for 4 weeks.
None Documented
None Documented
Terminal half-life approximately 55 hours (range 44-74 h), allowing once-daily dosing with steady state achieved in 2-3 weeks.
Terminal elimination half-life is approximately 30 hours, supporting once-daily topical application.
Primarily hepatic metabolism to active metabolite, then renal excretion of metabolites (55-70% in urine) and fecal (25-30%). Unchanged drug in urine <3%.
Primarily fecal (approximately 80% of administered dose recovered in feces as unchanged drug and metabolites) and renal (about 10%, predominantly as metabolites).
Category C
Category C
Topical Azole Antifungal
Topical Azole Antifungal